Article

Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial

Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Vaud, Switzerland
British medical journal (Clinical research ed.) 05/2003; 326(7399):1124. DOI: 10.1136/bmj.326.7399.1124
Source: PubMed

ABSTRACT To determine the subjective response to iron therapy in non-anaemic women with unexplained fatigue.
Double blind randomised placebo controlled trial.
Academic primary care centre and eight general practices in western Switzerland.
144 women aged 18 to 55, assigned to either oral ferrous sulphate (80 mg/day of elemental iron daily; n=75) or placebo (n=69) for four weeks.
Level of fatigue, measured by a 10 point visual analogue scale.
136 (94%) women completed the study. Most had a low serum ferritin concentration; <or= 20 microg/l in 69 (51%) women. Mean age, haemoglobin concentration, serum ferritin concentration, level of fatigue, depression, and anxiety were similar in both groups at baseline. Both groups were also similar for compliance and dropout rates. The level of fatigue after one month decreased by -1.82/6.37 points (29%) in the iron group compared with -0.85/6.46 points (13%) in the placebo group (difference 0.95 points, 95% confidence interval 0.32 to 1.62; P=0.004). Subgroups analysis showed that only women with ferritin concentrations <or= 50 microg/l improved with oral supplementation.
Non-anaemic women with unexplained fatigue may benefit from iron supplementation. The effect may be restricted to women with low or borderline serum ferritin concentrations.

Download full-text

Full-text

Available from: Bernard Favrat, Jun 22, 2015
0 Followers
 · 
132 Views
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Blood bankers have focused their energy to secure blood transfusion, and only recently have studies been published on the effect of blood donation on iron metabolism. In many facilities, hemoglobin measurement is only performed just before or even during blood donation, but the determination of iron stores is largely ignored. The 2013 paradox of transfusion medicine is due to the fact that blood donation may be harmful and leads to iron deficiency with or without anemia, but for other individuals, it may be a healthy measure preventing type 2 diabetes. The purpose of this review is to discuss iron metabolism in the perspective of blood donation, notably regarding their possible genetic profiles that eventually will discriminate "good" iron absorbers from "bad" iron responders.
    Blood reviews 10/2013; 27(6). DOI:10.1016/j.blre.2013.10.001 · 5.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure is a multifaceted pathophysiologic syndrome, with prevalent dysfunction of other vital organs and systems. The role of the liver in this disease has been little investigated, although up to 80% of patients with heart failure present with some form of liver dysfunction. In addition to its multiple metabolic functions, the liver has a crucial role in the removal of circulating endotoxins and in regulating immune responses and iron homeostasis. Kupffer cells that constitute 80% to 90% of tissue macrophages in the human body play an important role in this regard. A disturbed microcirculation of the liver may decrease endotoxin clearance and increase the hepatic secretion of proinflammatory cytokines. Such an immune activation may in turn alter the expression of hepcidin in the liver, resulting in iron deficiency. The proinflammatory state also is associated with an augmented free radical formation. However, the antioxidant capacity of the liver seems to be inadequate because there is evidence for selenium deficiency in patients with heart failure. The aim of this article was to summarize the various aspects of liver dysfunction in heart failure and to highlight the role of liver-derived factors in the development of specific nutritional deficiencies. Nutritional strategies opposing these deficiencies might present promising additive treatments of heart failure.
    Nutrition 09/2012; 29(2). DOI:10.1016/j.nut.2012.06.002 · 3.05 Impact Factor